Beyond Air, Inc. (NASDAQ:XAIR – Get Free Report)’s share price fell 2.1% during trading on Thursday. The stock traded as low as $2.30 and last traded at $2.31. Approximately 16,525 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 32,752 shares. The stock had previously closed at $2.36.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on XAIR. Weiss Ratings lowered Beyond Air from a “sell (e+)” rating to a “sell (e)” rating in a report on Wednesday, October 14th. Lake Street Capital assumed coverage on Beyond Air in a research report on Tuesday, September 1st. They set a “buy” rating and a $10.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.00.
Read Our Latest Stock Report on XAIR
Beyond Air Stock Performance
The company has a debt-to-equity ratio of 7.81, a quick ratio of 3.12 and a current ratio of 3.31. The firm’s 50-day moving average price is $3.10 and its two-hundred day moving average price is $10.85. The firm has a market capitalization of $2.22 million, a price-to-earnings ratio of -0.03 and a beta of 0.21.
Beyond Air (NASDAQ:XAIR – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($11.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($10.80) by ($0.20). The business had revenue of $1.77 million during the quarter, compared to the consensus estimate of $1.93 million. Beyond Air had a negative net margin of 435.71% and a negative return on equity of 440.26%.
About Beyond Air
Beyond Air, Inc is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders.
The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings.
Featured Stories
- Five stocks we like better than Beyond Air
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.
